用于结核病间歇化疗的各种异烟肼缓释基质制剂的评估。
Evaluation of various isoniazid slow releasing matrix preparations for intermittent chemotherapy of tuberculosis.
作者信息
Hodgkin M M, Eidus L, Hershfield E S
出版信息
Res Commun Chem Pathol Pharmacol. 1979 May;24(2):349-65.
The blood level achieved with 15 mg/kg ordinary isoniazid (INH) was compared with that obtained with INH slow releasing Matrix preparation. Three brands of INH Matrix preparation were compared namely: the product of ICN Canada Ltd, utilized by Laboratory Centre for Disease Control, the preparation of Smith and Nephew, Britain employed by the Tuberculosis unit of the British Medical Research Council and Tebesium, the product of Hefa-Frenon Arzneimittel, Germany studied by the Tuberculosis Unit of South African Medical Research Council. The results of this study showed that pharmacogenetic principle have to be taken into account, it is not possible to produce INH slow releasing Matrix preparate equally applicable for slow and fast acetylators of INH.
将15毫克/千克普通异烟肼（INH）所达到的血药浓度与使用INH缓释基质制剂所获得的血药浓度进行了比较。比较了三种品牌的INH基质制剂，即：加拿大ICN有限公司的产品，由疾病控制实验室中心使用；英国史赛克公司的制剂，由英国医学研究理事会结核病部门使用；以及德国赫法-弗雷农制药公司的产品特贝西姆，由南非医学研究理事会结核病部门研究。这项研究的结果表明，必须考虑药物遗传学原理，不可能生产出对INH慢乙酰化者和快乙酰化者同样适用的INH缓释基质制剂。
Zotero 插件